{"product_id":"pypd-five-forces","title":"(PYPD) PolyPid Ltd. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis PolyPid Ltd. Porter's Five Forces Analysis helps you understand the competitive pressures shaping the company’s market, including rivalry, buyer power, supplier power, substitutes, and new entrants. What you see here is a real preview of the actual report content, so you can review it before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized raw materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid relies on specialized polymer-lipid inputs and sterile-grade materials for its PLEX platform, so the supplier base is narrow. When only a few qualified vendors can meet GMP and regulatory specs, those suppliers hold more leverage over pricing and lead times. Any shortage or price hike can slow development work and squeeze margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. depends on GMP-certified contract makers and process partners for D-PLEX100, so suppliers with scarce quality capacity have more leverage. Changing a manufacturer can trigger revalidation, requalification, and regulatory review, which can take months and delay launch. That stickiness makes current GMP suppliers harder to replace and keeps supplier power high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and compliance barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. faces high supplier power because GMP, traceability, and stability rules cut the pool of qualified partners to only a few approved vendors. That can slow clinical and commercial supply, especially when one input affects product release or shelf life. In a 2025-2026 setting, even one failed audit or batch delay can block supply, so critical materials carry the strongest leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited dual sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd.'s supplier power is higher when niche inputs have no true backup source. In biopharma, dual sourcing is often planned but hard to fully qualify, so incumbent vendors can press on price and lead times. That risk matters most during pivotal trials and launch prep, when any delay can slow regulatory and commercial plans.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew qualified alternatives raise vendor leverage.\u003c\/li\u003e\n\u003cli\u003eLead-time risk is highest before launch.\u003c\/li\u003e\n\u003cli\u003eTrial supply gaps can delay milestones.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eService provider concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd. faces high supplier power because analytical labs, sterilization vendors, and logistics partners are often few in number and highly specialized. In clinical-stage work, a missed batch release or weak regulatory file can push trial timelines back and raise costs fast. Supplier bottlenecks can matter even more when capacity is tight and documentation quality is a gatekeeper.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized vendors are hard to replace.\u003c\/li\u003e\n\u003cli\u003eCapacity limits can delay trials.\u003c\/li\u003e\n\u003cli\u003eBad documentation can block release.\u003c\/li\u003e\n\u003cli\u003eDelays hit clinical-stage cash burn hard.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid Faces High Supplier Power and Launch Delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. has high supplier power because GMP-certified inputs, sterile materials, and contract makers are scarce and hard to replace. Requalification after a switch can take months, so vendors can push on price and lead times. That raises trial and launch risk, especially when one batch delay can stall regulatory milestones.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified vendors\u003c\/td\u003e\n\u003ctd\u003eFew\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching time\u003c\/td\u003e\n\u003ctd\u003eMonths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier power\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses PolyPid Ltd.’s competitive pressures, supplier and buyer power, substitutes, and entry risks shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick five-forces snapshot for PolyPid Ltd.—cutting through market pressure, competition, and supplier risk in one clear view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for PolyPid Ltd., boosting credibility and helping decision-makers verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital purchasing power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid’s buyers are hospitals, surgical centers, and integrated health systems, and they push hard on price, evidence, and reimbursement. U.S. hospital operating margins stayed thin in 2025, near 1% to 2%, so procurement teams demand clear savings before they add a new product. Large group purchasing organizations can also slow adoption until clinical data and cost offsets are proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormulary and committee gates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCustomer power is high because D-PLEX100 buying decisions can pass through pharmacy, infection control, and surgical committees, giving hospitals several veto points. US CDC data show surgical site infections affect about 2% to 4% of inpatient surgeries, so buyers compare any new product against low-cost prevention bundles. If D-PLEX100 does not show clear benefit over existing protocols, institutional buyers can delay or reject adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayer reimbursement pressure is high for PolyPid Ltd. in SSI prevention, because hospitals want proof that a premium product cuts total cost, not just complications. Surgical site infections affect about 2% to 5% of procedures and can add roughly $11,000 to $26,000 per case, so buyers demand clear budget impact data before adoption. That makes customers tougher in commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSurgeon and clinician influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSurgeons strongly shape adoption at PolyPid Ltd. because they choose what goes into the OR, but hospitals still control the budget and can wait for proof. One clean message: clinical buy-in is not the same as purchase power.\u003c\/p\u003e\n\u003cp\u003eThat makes customer power high when buyers ask for Phase III and real-world evidence before scaling use. If clinicians split on value, hospitals can delay uptake, compare alternatives, and push harder on price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSurgeons drive use, not budget.\u003c\/li\u003e\n\u003cli\u003eHospitals want Phase III proof.\u003c\/li\u003e\n\u003cli\u003eReal-world data speeds wider adoption.\u003c\/li\u003e\n\u003cli\u003eClinician split raises buyer power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAvailability of low-cost alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuyers have strong fallback options because standard antibiotic prophylaxis and established infection-prevention bundles are already built into routine care. In 2025\/2026, that means PolyPid Ltd. must compete against familiar, widely used, and usually low-cost protocols, which keeps pricing power tight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStandard care is easy to adopt.\u003c\/li\u003e\n\u003cli\u003eExisting bundles lower switching costs.\u003c\/li\u003e\n\u003cli\u003eLow-cost alternatives cap pricing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe easier it is to stay with existing protocols, the more customer bargaining power rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid Faces Strong Buyer Pressure Amid Tight Hospital Budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer bargaining power for PolyPid Ltd. is high because hospitals, surgeons, and GPOs all weigh in, while buyers can stay with low-cost standard SSI prevention bundles. Thin 2025 hospital margins near 1% to 2% and SSI rates of about 2% to 5% keep pricing pressure tight. Adoption still depends on clear Phase III and reimbursement proof.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital margins\u003c\/td\u003e\n\u003ctd\u003e~1% to 2% in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI rate\u003c\/td\u003e\n\u003ctd\u003e~2% to 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtra cost per SSI\u003c\/td\u003e\n\u003ctd\u003e$11,000 to $26,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePolyPid Ltd. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact PolyPid Ltd. Porter’s Five Forces Analysis you’ll receive after purchase—no placeholders, no edits, no surprises. It’s the same professionally written, ready-to-use document displayed here for immediate review. Once you buy, you’ll get instant access to this exact file in the same format.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded infection-prevention space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high because SSI prevention spans pharmaceuticals, antiseptics, device coatings, and procedural bundles, so PolyPid faces many substitute approaches, not one clear rival. SSIs still affect about 2%–5% of surgical patients, and U.S. hospitals report roughly 110,000+ SSIs a year, which keeps many players active in the market. That broad choice set raises pricing pressure and makes product differentiation critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage evidence race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. is in a late-stage evidence race where Phase III data can decide regulatory success and market trust. In biopharma, rivals with stronger efficacy, safety, or trial-design data can quickly take share, especially when pivotal readouts are the main value driver. PolyPid’s Phase III program makes every endpoint and adverse-event rate matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferentiation challenge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eD-PLEX100 faces a sharp differentiation test: it must show better results than standard prophylaxis, where surgical-site infection rates after colorectal surgery can still be about 10% to 30%. If its clinical and health-economic gains are not clear, physicians may stay with familiar wound-care tools. Weak differentiation makes competitive rivalry harsher.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and launch timing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory milestones and label scope can decide who locks in first-mover advantage. If another Company reaches approval first, it can build hospital habits and contract ties before PolyPid Ltd., raising PolyPid Ltd.’s market-access and education spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eFirst approval shapes buying habits\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBroader labels widen contract reach\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLate entry means higher launch spend\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn this race, even a few quarters’ delay can shift revenue and pricing power to the early mover.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical evidence competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedical evidence is the main battleground, because rivals win with head-to-head trials, meta-analyses, and real-world outcomes, not just product features. In surgical site infection care, the 2%-5% infection rate after surgery makes even small proof gaps matter for adoption and hospital budgets. Stronger publication records and guideline inclusion can push pricing pressure higher on PolyPid Ltd.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHead-to-head data drives share\u003c\/li\u003e\n\u003cli\u003eGuidelines shape hospital uptake\u003c\/li\u003e\n\u003cli\u003eBetter evidence weakens pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid Faces Intense SSI Competition and Pricing Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for PolyPid Ltd. because SSI prevention spans drugs, antiseptics, coatings, and care bundles, so the company faces many substitutes, not one rival. With SSIs still affecting about 2%–5% of surgical patients, pricing pressure stays real.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI rate\u003c\/td\u003e\n\u003ctd\u003e2%–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eColorectal SSI rate\u003c\/td\u003e\n\u003ctd\u003e10%–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey rivalry driver\u003c\/td\u003e\n\u003ctd\u003ePhase III evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eD-PLEX100 must prove clear clinical and health-economic gains, or hospitals may stay with familiar tools. First approval and stronger trial data can quickly shift buying habits and share.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard antibiotic prophylaxis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard perioperative antibiotic prophylaxis is the main substitute for PolyPid Ltd.'s localized delivery approach. These regimens are already built into hospital protocols, are low cost, and use generic antibiotics that often cost only a few dollars per dose, so many surgeons see them as enough protection.\u003c\/p\u003e\n\u003cp\u003eThat matters because surgical site infections still affect about 2% to 5% of inpatient procedures, but if current prophylaxis is judged adequate, demand for a new product can stay weak.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfection-prevention bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals already cut surgical site infections (SSIs) with bundled care: antiseptic prep, sterile technique, glucose control, and warming protocols. In recent studies, bundled protocols have cut SSI rates by about 30% to 50% without a new drug, so the substitute is real and cheap. For PolyPid Ltd., strong bundle results raise threat of substitutes, especially when hospitals want lower-cost prevention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther wound-care technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNegative pressure wound therapy and advanced dressings can replace a prophylactic drug-device approach in some surgeries. SSI remains costly: CDC-linked estimates put added cost at about $11,000 to $29,000 per infection, so buyers have strong incentives to choose the lowest-risk option. That broad menu of wound-care tools gives hospitals another way to manage SSI risk without using PolyPid Ltd.'s platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAntimicrobial materials and coatings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAntimicrobial coatings, impregnated dressings, and local-release materials can meet the same infection-prevention goal as D-PLEX100, so they act as partial substitutes in surgeon and hospital buying choices. Surgical site infections affect about 2% to 5% of operations, with treatment costs often running into thousands of dollars per case, so buyers compare protection, price, and ease of use. That keeps substitute pressure real.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartial, not direct, substitutes\u003c\/li\u003e\n\u003cli\u003eCompete on infection prevention\u003c\/li\u003e\n\u003cli\u003eBuying choice depends on cost and workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProcess and protocol improvements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcess and protocol improvements are a real substitute for PolyPid Ltd.’s therapy because better surgical technique, faster procedures, and enhanced recovery pathways can lower infection risk without adding a new drug cost. In many hospitals, ERAS can cut length of stay by 1 to 3 days, so the economic case for a new infection-prevention therapy weakens when these protocols work well.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShorter procedures reduce exposure time.\u003c\/li\u003e\n\u003cli\u003eERAS can trim 1-3 hospital days.\u003c\/li\u003e\n\u003cli\u003eLower-cost protocols weaken pricing power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAs these protocols become more effective, the substitution threat rises because hospitals may prefer process fixes that fit existing budgets and workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Substitute Risk Keeps D-PLEX100 Under Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for PolyPid Ltd. stays high because hospitals can use generic prophylactic antibiotics, SSI bundles, and ERAS instead of D-PLEX100. Bundled care has cut SSI rates by 30% to 50%, while SSI still affects about 2% to 5% of inpatient procedures, so buyers keep comparing cheaper process fixes with new therapy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric antibiotics\u003c\/td\u003e\n\u003ctd\u003eLow cost, embedded in protocols\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI bundles\u003c\/td\u003e\n\u003ctd\u003e30%-50% SSI cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eERAS\u003c\/td\u003e\n\u003ctd\u003e1-3 fewer hospital days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn biopharma, moving a surgical product to market can take 7-10 years and more than $1 billion, with GMP controls and pivotal trials adding cost and delay. In 2025, the FDA approved only 50 novel drugs, showing how selective the bar remains. That keeps serious new entrants to a small set of well-funded players.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital-intensive development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants is low because late-stage biotech work is expensive: one Phase 3 program can cost tens of millions, and FDA drug development often takes 10 to 15 years and more than $1 billion. New firms must fund trials, GMP quality systems, and market access before any sales start, so the cash burn is heavy. That burden shuts out smaller challengers and protects PolyPid Ltd. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP and platform protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.’s PLEX platform and product-specific patents can block fast imitation, because rivals need both legal freedom and deep know-how to copy the drug-release system. If the patent estate is broad and durable, entry looks less attractive and launch costs rise. That kind of protection matters most when one platform supports multiple products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical credibility hurdle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical credibility is a real entry barrier in surgery. Buyers usually want randomized, peer-reviewed proof from trusted investigators, and clinical adoption can stall if that proof is thin. With surgical site infections still affecting about 2% to 5% of procedures, a new entrant must build evidence and physician trust from zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eTrusted studies drive surgeon adoption.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEvidence build-out starts from scratch.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eWeak publication support slows uptake.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and scale complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd. faces a low threat from new entrants because sterile, reproducible manufacturing for a specialty therapeutic is hard to build and validate. New players must prove consistent quality, stability, and supply reliability before hospitals will sign contracts, and that takes time, capital, and process control.\u003c\/p\u003e\n\u003cp\u003eThis scale gap matters in sterile pharma, where one failed batch or supply break can block adoption and raise switching risk for buyers. So the operational bar stays high and fast entry stays limited.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSterile output must stay consistent\u003c\/li\u003e\n\u003cli\u003eHospital buyers demand supply reliability\u003c\/li\u003e\n\u003cli\u003eValidation and quality take time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s New Entrant Barrier: High Cost, Long Timelines, Low Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for PolyPid Ltd. stays low. Late-stage drug work can take 10-15 years and cost over $1 billion, while the FDA approved only 50 novel drugs in 2025. New rivals also face patent, sterile manufacturing, and surgeon-trust barriers before first sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment\u003c\/td\u003e\n\u003ctd\u003e10-15 years, $1B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA 2025\u003c\/td\u003e\n\u003ctd\u003e50 novel drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial proof\u003c\/td\u003e\n\u003ctd\u003eRCTs and GMP needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234839142665,"sku":"pypd-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pypd-five-forces.webp?v=1785729445","url":"https:\/\/dcfanalyst.com\/products\/pypd-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}